SecBot SecBot
PRESS-RELEASE ·Filed Mar 30, 2026

PDSB

PDS Biotechnology Corporation
MIXED
Impact 6/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The trial design change improves the near-term regulatory pathway for PDS0101, potentially accelerating value inflection, but the shrinking cash balance (~$26.7M) relative to operating costs (~$31.5M in 2025) suggests a capital raise is likely within the next 9–12 months, which would be dilutive. Monitor upcoming clinical updates on PDS01ADC and enrollment progress in the amended VERSATILE-003 trial.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.5370
T+0 close · Mar 30, 2026 · via day close
Latest settled
+66.48%
T+60 · $0.8940
Vs SPY
+49.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 30 $0.5370entry
  2. T+1 · 8mo ago +12.66%α +9.77% · $0.6050
  3. T+5 · 7mo ago +70.95%α +66.65% · $0.9180
  4. T+20 · 7mo ago +101.12%α +88.52% · $1.08
  5. T+60 · 5mo ago +66.48%α +49.99% · $0.8940
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PDS Biotechnology reported financial results for 2025 and provided a clinical update, including a Phase 3 trial amendment for its lead candidate PDS0101 to incorporate progression-free survival as an interim primary endpoint, which could enable accelerated approval in HPV16-positive head and neck cancer. The company reduced operating expenses and improved net loss compared to 2024, but ended the year with $26.7 million in cash, down from $41.7 million, raising concerns about runway. Early data from a PDS01ADC trial showed promising median PFS of 9.6 months in prostate cancer.

Key Financial Metrics

EPS
$-34495504.00

Key Facts

  • Net loss for 2025 was $34.5 million ($0.74/share), improved from $37.6 million ($1.03/share) in 2024.
  • R&D expenses decreased to $19.0 million from $22.6 million in 2024, driven by lower manufacturing and personnel costs.
  • Cash balance declined to $26.7 million as of December 31, 2025, from $41.7 million in 2024, a 36% reduction.
  • Amended VERSATILE-003 Phase 3 trial to include PFS as an interim primary endpoint to potentially accelerate approval for PDS0101.
  • Early PDS01ADC + docetaxel data in mCRPC showed 9.6 months median PFS and 40% median PSA decline.
  • New U.S. and Japanese patents extend PDS0101 IP protection into the 2040s.

Financial Impact

Reduced annual operating expenses by $4.8 million, but cash burn remains high at ~$15 million net reduction in cash year-over-year.

net_losscashr_and_d_expenseoperating_expense

Risk Factors

  • Cash runway may be insufficient to reach key milestones without dilutive financing.
  • Accelerated approval pathway depends on PFS data, which may not confirm OS benefit.
  • Forward-looking statements dominate messaging; clinical progress remains early-stage.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3264482

Track record

28 reports on PDSB

Performance horizon

7 of 14 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 14 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
  2. Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
  3. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
  4. Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  6. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
  7. Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
  8. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
  9. Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
  10. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 30, 2026